SUTAB is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults. It is a tablet formulation of lubiprostone, a chloride channel activator that works by increasing fluid secretion in the intestines, which helps to soften stool and promote bowel movements.

SUTAB was approved by the US Food and Drug Administration (FDA) in 2018 [1]. The medication is available in 24 mg tablets and is typically taken once daily with a glass of water.

According to DrugPatentWatch.com, the patent for SUTAB is set to expire in 2029 [2]. This means that generic versions of the medication may become available after that date, which could lead to increased competition and potentially lower prices.

The efficacy and safety of SUTAB have been evaluated in clinical trials, which have shown that it can improve bowel habits and reduce symptoms of IBS-C and CIC [3]. Common side effects of SUTAB include nausea, diarrhea, and abdominal pain.

Overall, SUTAB is a treatment option for adults with IBS-C and CIC, and its availability and pricing may change in the future as the patent expires.

Sources:
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-irritable-bowel-syndrome-constipation
[2] https://www.drugpatentwatch.com/patent/US-10319151
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461246/